Journal of Autism and Developmental Disorders

, Volume 39, Issue 12, pp 1629–1635

Open-Label Memantine in Fragile X Syndrome

Authors

    • Department of PsychiatryIndiana University School of Medicine
    • Christian Sarkine Autism Treatment CenterJames Whitcomb Riley Hospital for Children
  • Jennifer E. Mullett
    • Department of PsychiatryIndiana University School of Medicine
    • Christian Sarkine Autism Treatment CenterJames Whitcomb Riley Hospital for Children
  • Christopher J. McDougle
    • Department of PsychiatryIndiana University School of Medicine
    • Christian Sarkine Autism Treatment CenterJames Whitcomb Riley Hospital for Children
Original Paper

DOI: 10.1007/s10803-009-0807-3

Cite this article as:
Erickson, C.A., Mullett, J.E. & McDougle, C.J. J Autism Dev Disord (2009) 39: 1629. doi:10.1007/s10803-009-0807-3

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

Keywords

MemantineFragile X syndromeInattentionHyperactivitySocial withdrawalIrritability

Copyright information

© Springer Science+Business Media, LLC 2009